

A collection of misleading surrogate end points

Staffan Svensson and Healthy Skepticism members

November 20, 2008

Drug(s)	Surrogate end point	Hard end point	Reference
Encainide, flecainide	↓ Premature depolarizations	↑ Cardiac death & arrest	[1]
Doxazosine	↓ Blood pressure	↑ Heart failure	[2]
Estrogen, progestin	↓ Cholesterol	↑ Stroke, dementia, breast cancer	[3]
Torcetrapib	↓ Cholesterol	↑ Mortality	[4]
Nesiritide	↓ Wedge pressure, dyspnoea	↑ Mortality	[5]
Fluoride	↑ Bone mineral density	↑ Nonvertebral fractures	[6]
Rosiglitazone	↓ S-HbA _{1c}	↑ Myocardial infarction	[7]
Intensive treatment in Diabetes type 2	↓ S-HbA _{1c} < 6%	↑ Mortality	[8]
Milrinone	↑ Cardiac contractility	↑ Mortality	[9]
Ibopamine	↑ Cardiac contractility	↑ Mortality	[10]
Epoprostenol	↑ Cardiac contractility	↑ Mortality	[11]
Tolbutamide, phenformin	↓ Blood glucose	↑ Mortality	[12]
Erythropoietin	↑ Hemoglobin in chronic renal failure	↑ Mortality	[13]
Aprotinin	↓ Blood loss in cardiac surgery	↑ Mortality	[14]
Metoprolol	↓ Perioperative ischaemia	↑ Mortality	[15]
Clofibrate	↓ Cholesterol	↑ Mortality	[16]

Table 1: The table

References

- [1] Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med.* 1991 Mar;324(12):781–788.
- [2] ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA.* 2000 Apr;283(15):1967–1975.
- [3] Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. *JAMA.* 2002 Jul;288(3):321–333.
- [4] Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med.* 2007 Nov;357(21):2109–2122.
- [5] Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. *JAMA.* 2005 Apr;293(15):1900–1905.
- [6] Haguenaer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. *Osteoporos Int.* 2000;11(9):727–738.
- [7] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med.* 2007 Jun;356(24):2457–2471.
- [8] Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008 Jun;358(24):2545–2559.
- [9] Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N Engl J Med.* 1991 Nov;325(21):1468–1475.
- [10] Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Ran-

domised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. *Lancet*. 1997 Apr;349(9057):971–977.

- [11] Califf RM, Adams KF, McKenna WJ, Gheorghide M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). *Am Heart J*. 1997 Jul;134(1):44–54.
- [12] University Group Diabetes Program. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. *Diabetes*. 1975;24 Suppl 1:65–184.
- [13] Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. *Lancet*. 2007 Feb;369(9559):381–388.
- [14] Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med*. 2008 May;358(22):2319–2331.
- [15] Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. *Lancet*. 2008 May;371(9627):1839–1847.
- [16] Oliver MF, et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. *Br Heart J*. 1978 Oct;40(10):1069–1118.